[Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma].

The aim of the present investigation was to evaluate the diagnostic accuracy of positron emission tomography with 18-fluoro-2-deoxyglucose (FDG-PET) in the detection of recurrent lung cancer. PET was performed using an ECAT ART scanner (Siemens CTI) after i.v.

[Brain metastases of lung cancer: diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDG-PET)].

The value of FDG-PET in oncology is currently investigated in clinical studies. There is only limited information on the usefulness of FDG-PET in the evaluation of distant metastases of lung cancer. The purpose of the present prospective investigation was to determine the diagnostic accuracy of FDG-PET in the detection of brain metastases of lung cancer.

[Unusual metastasis of a malignant pleural mesothelioma].

Usually malignant pleural mesothelioma causes pain and dyspnoea due to local invasion of the chest wall and compression of the lung. Distant metastases rarely cause symptoms. We report on a patient with an epithelial subtype of malignant pleural mesothelioma who presented himself after chemo- and immunotherapy with shortness of breath and loss of weight due to a temporo-mandibular joint and a new nodular shadow in the contralateral lung.

A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

Paclitaxel is a new antineoplastic agent with activity in lung cancer. This phase I clinical trial was designed to determine the maximum tolerated dose (MTD) of paclitaxel in combination with etoposide in previously untreated patients with non-small cell lung cancer (NSCLC). Doses of paclitaxel were in the range of 150-225 mg/m2 (d1) and of etoposide in the range of 100-120 mg/m2 (d2-4).

[Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].

There is evidence that neoadjuvant chemotherapy may improve treatment results in patients with locally advanced NSCLC. The aim of the present study was to increase resectability rates by induction chemotherapy in NSCLC stage IIIA/IIIB with the new cytostatic combination, paclitaxel and carboplatin. Neoadjuvant treatment consisted of 3 cycles (q21) of chemotherapy with paclitaxel (200 mg/m(2)) and carboplatin (AUC 6).